as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 29 Sep 2026
₹234.71
Change
-6.31 (-2.62%)
Open
₹239.02
Prev. Close
₹241.02
Day High
₹240.87
Day Low
₹232.3
Volume Analysis
Traded
93,102
Delivered
40,453
Delivery %
43.45%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹248.19 | ₹244.53 | ₹239.62 | ₹235.96 | ₹231.05 | ₹227.39 | ₹222.48 |
| Fibonacci | ₹244.53 | ₹241.26 | ₹239.23 | ₹235.96 | ₹232.69 | ₹230.66 | ₹227.39 |
| Camarilla | ₹237.07 | ₹236.28 | ₹235.5 | ₹235.96 | ₹233.92 | ₹233.14 | ₹232.35 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+21.91%
1 Week
+4.02%
1 Month
-2.55%
3 Months
-0.14%
6 Months
+26.04%
1 Year
+7.04%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 30 Sep 2026. Not investment advice.
TopFund Analysis
Jagsonpal Pharmaceuticals lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 61/100. The strongest factor is Corporate Governance (85/100), while Liquidity (28/100) is the weakest area to weigh before deciding. FII holding has been rising.
TopFund Score — Fundamentals Quality
61/100 — AverageData confidence: 60/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 29 Sep 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Jagsonpal signs BTA to acquire Group Pharma’s Wellness Portfolio for ₹23.7 crore, up to ₹46.7 crore total.
Jagsonpal signs BTA to acquire Group Pharma wellness portfolio for up to ₹46.7 crore, closing by 1 Nov 2026.
47th AGM held on September 18, 2026; FY26 accounts, dividend, director appointments approved.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 30.07% | 30.16% | 30.33% | 30.01% | 29.63% | 30.1% | 30.11% | 30.12% | 30.25% | 30.34% | 29.44% | 28.04% |
| Promoters | 68.72% | 68.48% | 68.09% | 68.04% | 67.98% | 67.82% | 67.77% | 67.65% | 67.54% | 67.39% | 67.89% | 69.06% |
| FII | 0.38% | 0.53% | 0.73% | 1.1% | 2.3% | 2.1% | 2.1% | 2.17% | 2.12% | 2.12% | 2.44% | 2.3% |
| DII | 0.82% | 0.82% | 0.84% | 0.84% | 0.11% | 0.0% | 0.0% | 0.05% | 0.08% | 0.15% | 0.22% | 0.62% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Jagsonpal Pharmaceuticals (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 444,405 | 35.2 | 5.32 | 16.0% |
| Divi S Laboratories Ltd | 253,694 | 85.2 | 15.14 | 16.5% |
| Torrent Pharmaceuticals L | 189,746 | 85.0 | 20.11 | 27.4% |
| Apollo Hospitals Enter. L | 128,055 | 60.9 | 13.51 | 21.2% |
| Zydus Lifesciences Ltd | 120,089 | 24.7 | 4.48 | 21.2% |
| Cipla Ltd | 111,985 | 31.3 | 3.25 | 11.6% |
Which Mutual Funds Hold Jagsonpal Pharmaceuticals?
Frequently Asked Questions about Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals (JAGSNPHARM) closed at ₹234.71 on NSE on 29 September 2026, down 6.31 (2.62%) from the previous close.
Jagsonpal Pharmaceuticals trades on the NSE (National Stock Exchange of India) under the symbol JAGSNPHARM.
Jagsonpal Pharmaceuticals has a TopFund Quality Score of 61/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Jagsonpal Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.